ArticlePLoS pathogens2009
A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.
Article in PLoS pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Analysis of CDR3 Sequences from T-Cell Receptor β in Acute Respiratory Distress Syndrome.Biomolecules · 2023Article
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- An updated review and current challenges of Guanarito virus infection, Venezuelan hemorrhagic fever.Archives of virology · 2022Review
- Review
- Article
- Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.Vaccine · 2020Article
- Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.Frontiers in immunology · 2020Review
- Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.Immunologic research · 2016Article
- Native functionality and therapeutic targeting of arenaviral glycoproteins.Current opinion in virology · 2016Review
- VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Human vaccines & immunotherapeutics · 2014Review
- Properties of MHC class I presented peptides that enhance immunogenicity.PLoS computational biology · 2013Article
- Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.Current protocols in immunology · 2013Article
- Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.PLoS pathogens · 2013Review
- Universal fungal vaccines: could there be light at the end of the tunnel?Human vaccines & immunotherapeutics · 2012Review
- T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.Journal of immunological methods · 2011Review
- Human CD8⁺ and CD4⁺ T cell memory to lymphocytic choriomeningitis virus infection.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
Arenaviruses are the causative pathogens of severe hemorrhagic fever and aseptic meningitis in humans, for which no licensed vaccines are currently available. Pathogen heterogeneity within the Arenaviridae family poses a significant challenge for vaccine development. The main hypothesis we tested in the present study was whether it is possible to design a universal vaccine strategy capable of inducing simultaneous HLA-restricted CD8+ T cell responses against 7 pathogenic arenaviruses (including the lymphocytic choriomeningitis, Lassa, Guanarito, Junin, Machupo, Sabia, and Whitewater Arroyo viruses), either through the identification of widely conserved epitopes, or by the identification of a collection of epitopes derived from multiple arenavirus species. By inoculating HLA transgenic mice with a panel of recombinant vaccinia viruses (rVACVs) expressing the different arenavirus proteins, we identified 10 HLA-A02 and 10 HLA-A03-restricted epitopes that are naturally processed in human antigen-presenting cells. For some of these epitopes we were able to demonstrate cross-reactive CD8+ T cell responses, further increasing the coverage afforded by the epitope set against each different arenavirus species. Importantly, we showed that immunization of HLA transgenic mice with an epitope cocktail generated simultaneous CD8+ T cell responses against all 7 arenaviruses, and protected mice against challenge with rVACVs expressing either Old or New World arenavirus glycoproteins. In conclusion, the set of identified epitopes allows broad, non-ethnically biased coverage of all 7 viral species targeted by our studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.